371 related articles for article (PubMed ID: 16822720)
1. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy.
Beckles DL; Mascareno E; Siddiqui MA
Vascul Pharmacol; 2006 Dec; 45(6):350-7. PubMed ID: 16822720
[TBL] [Abstract][Full Text] [Related]
2. Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon.
Klein G; Schaefer A; Hilfiker-Kleiner D; Oppermann D; Shukla P; Quint A; Podewski E; Hilfiker A; Schröder F; Leitges M; Drexler H
Circ Res; 2005 Apr; 96(7):748-55. PubMed ID: 15761199
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis.
Gao XM; Wong G; Wang B; Kiriazis H; Moore XL; Su YD; Dart A; Du XJ
J Hypertens; 2006 Aug; 24(8):1663-70. PubMed ID: 16877971
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome.
Li R; Yang N; Zhang L; Huang Y; Zhang R; Wang F; Luo M; Liang Y; Yu X
Am J Nephrol; 2007; 27(6):580-9. PubMed ID: 17823504
[TBL] [Abstract][Full Text] [Related]
5. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.
Kemi OJ; Ceci M; Wisloff U; Grimaldi S; Gallo P; Smith GL; Condorelli G; Ellingsen O
J Cell Physiol; 2008 Feb; 214(2):316-21. PubMed ID: 17941081
[TBL] [Abstract][Full Text] [Related]
6. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure.
Li XM; Ma YT; Yang YN; Liu F; Chen BD; Han W; Zhang JF; Gao XM
Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1054-61. PubMed ID: 19566828
[TBL] [Abstract][Full Text] [Related]
8. 17beta-estradiol attenuates the development of pressure-overload hypertrophy.
van Eickels M; Grohé C; Cleutjens JP; Janssen BJ; Wellens HJ; Doevendans PA
Circulation; 2001 Sep; 104(12):1419-23. PubMed ID: 11560859
[TBL] [Abstract][Full Text] [Related]
9. Loss of TRADD attenuates pressure overload-induced cardiac hypertrophy through regulating TAK1/P38 MAPK signalling in mice.
Wu L; Cao Z; Ji L; Mei L; Jin Q; Zeng J; Lin J; Chu M; Li L; Yang X
Biochem Biophys Res Commun; 2017 Feb; 483(2):810-815. PubMed ID: 28013046
[TBL] [Abstract][Full Text] [Related]
10. Cardiac effects of osteostatin in mice.
Meyer R; Schreckenberg R; Kraus D; Kretschmer F; Schulz R; Schlüter KD
J Physiol Pharmacol; 2012 Feb; 63(1):17-22. PubMed ID: 22460456
[TBL] [Abstract][Full Text] [Related]
11. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice.
Wang S; Yang N; Zhang L; Huang B; Tan H; Liang Y; Li Y; Yu X
Lupus; 2010 Sep; 19(10):1171-80. PubMed ID: 20501525
[TBL] [Abstract][Full Text] [Related]
12. Role of a Janus kinase 2-dependent signaling pathway in platelet activation.
Lu WJ; Lin KC; Huang SY; Thomas PA; Wu YH; Wu HC; Lin KH; Sheu JR
Thromb Res; 2014 Jun; 133(6):1088-96. PubMed ID: 24731555
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Liao Y; Zhao H; Ogai A; Kato H; Asakura M; Kim J; Asanuma H; Minamino T; Takashima S; Kitakaze M
Hypertens Res; 2008 Feb; 31(2):335-44. PubMed ID: 18360054
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality.
Hui L; Yao Y; Wang S; Yu Y; Dong N; Li H; Sheng Z
J Trauma; 2009 Mar; 66(3):859-65. PubMed ID: 19276765
[TBL] [Abstract][Full Text] [Related]
15. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
Zhao M; Zhang J; Xu Y; Liu J; Ye J; Wang Z; Ye D; Feng Y; Xu S; Pan W; Wang M; Wan J
Int Immunopharmacol; 2021 Oct; 99():108046. PubMed ID: 34435581
[TBL] [Abstract][Full Text] [Related]
16. Alamandine improves cardiac remodeling induced by transverse aortic constriction in mice.
Silva MM; de Souza-Neto FP; Jesus ICG; Gonçalves GK; Santuchi MC; Sanches BL; de Alcântara-Leonídio TC; Melo MB; Vieira MAR; Guatimosim S; Santos RAS; da Silva RF
Am J Physiol Heart Circ Physiol; 2021 Jan; 320(1):H352-H363. PubMed ID: 33124885
[TBL] [Abstract][Full Text] [Related]
17. IL-6 attenuates trimethyltin-induced cognitive dysfunction via activation of JAK2/STAT3, M1 mAChR and ERK signaling network.
Kim BK; Tran HY; Shin EJ; Lee C; Chung YH; Jeong JH; Bach JH; Kim WK; Park DH; Saito K; Nabeshima T; Kim HC
Cell Signal; 2013 Jun; 25(6):1348-60. PubMed ID: 23499905
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress.
Zhao H; Liao Y; Minamino T; Asano Y; Asakura M; Kim J; Asanuma H; Takashima S; Hori M; Kitakaze M
Hypertens Res; 2008 Oct; 31(10):1977-87. PubMed ID: 19015605
[TBL] [Abstract][Full Text] [Related]
19. Endothelial nitric oxide synthase of the bone marrow regulates myocardial hypertrophy, fibrosis, and angiogenesis.
Kazakov A; Müller P; Jagoda P; Semenov A; Böhm M; Laufs U
Cardiovasc Res; 2012 Mar; 93(3):397-405. PubMed ID: 22106415
[TBL] [Abstract][Full Text] [Related]
20. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling.
Zhu Y; Li T; Song J; Liu C; Hu Y; Que L; Ha T; Kelley J; Chen Q; Li C; Li Y
Basic Res Cardiol; 2011 Sep; 106(5):787-99. PubMed ID: 21533832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
